Direct-to-consumer genetic testing company 23andMe announced earlier this week that it has received its first patent. As our sister publication BioArray News reports, the patent, US Patent No. 8,187,811, covers a method for determining an individual's susceptibility to Parkinson's disease.
To read the full story....
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.